Nothing Special   »   [go: up one dir, main page]

NO992102L - Peptidblanding, samt farmasøytisk sammensetning og kreftvaksine som innbefatter peptidblandingen - Google Patents

Peptidblanding, samt farmasøytisk sammensetning og kreftvaksine som innbefatter peptidblandingen

Info

Publication number
NO992102L
NO992102L NO992102A NO992102A NO992102L NO 992102 L NO992102 L NO 992102L NO 992102 A NO992102 A NO 992102A NO 992102 A NO992102 A NO 992102A NO 992102 L NO992102 L NO 992102L
Authority
NO
Norway
Prior art keywords
composition
peptide composition
well
peptide
cancer vaccine
Prior art date
Application number
NO992102A
Other languages
English (en)
Other versions
NO309798B1 (no
NO992102D0 (no
Inventor
Jon Amund Eriksen
Marianne Klemp Gjertsen
Gustav Gaudernack
Mona Moeller
Original Assignee
Norsk Hydro As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Norsk Hydro As filed Critical Norsk Hydro As
Priority to NO19992102A priority Critical patent/NO309798B1/no
Publication of NO992102D0 publication Critical patent/NO992102D0/no
Priority to CA002372187A priority patent/CA2372187A1/en
Priority to PCT/NO2000/000142 priority patent/WO2000066153A1/en
Priority to ARP000102059A priority patent/AR023806A1/es
Priority to JP2000615037A priority patent/JP2002543149A/ja
Priority to AU44389/00A priority patent/AU4438900A/en
Priority to EP00925746A priority patent/EP1173199A1/en
Publication of NO992102L publication Critical patent/NO992102L/no
Publication of NO309798B1 publication Critical patent/NO309798B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001154—Enzymes
    • A61K39/001164—GTPases, e.g. Ras or Rho
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO19992102A 1999-04-30 1999-04-30 Peptidblanding, samt farmasoytisk sammensetning og kreftvaksine som innbefatter peptidblandingen NO309798B1 (no)

Priority Applications (7)

Application Number Priority Date Filing Date Title
NO19992102A NO309798B1 (no) 1999-04-30 1999-04-30 Peptidblanding, samt farmasoytisk sammensetning og kreftvaksine som innbefatter peptidblandingen
CA002372187A CA2372187A1 (en) 1999-04-30 2000-04-28 Ras oncogen p21 peptide vaccines
PCT/NO2000/000142 WO2000066153A1 (en) 1999-04-30 2000-04-28 RAS ONCOGEN p21 PEPTIDE VACCINES
ARP000102059A AR023806A1 (es) 1999-04-30 2000-04-28 Uso de una mezcla de peptidos para la manufactura de un agente terapeutico para la profilaxis y/o el tratamiento del cancer, las composicionesfarmaceuticas y vacunas que contienen dicha mezcla y los procedimientos de preparacion de dichas composiciones y vacunas
JP2000615037A JP2002543149A (ja) 1999-04-30 2000-04-28 ＲＡＳオンコージンｐ２１ペプチドワクチン
AU44389/00A AU4438900A (en) 1999-04-30 2000-04-28 Ras oncogen p21 peptide vaccines
EP00925746A EP1173199A1 (en) 1999-04-30 2000-04-28 RAS ONCOGEN p21 PEPTIDE VACCINES

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
NO19992102A NO309798B1 (no) 1999-04-30 1999-04-30 Peptidblanding, samt farmasoytisk sammensetning og kreftvaksine som innbefatter peptidblandingen

Publications (3)

Publication Number Publication Date
NO992102D0 NO992102D0 (no) 1999-04-30
NO992102L true NO992102L (no) 2000-10-31
NO309798B1 NO309798B1 (no) 2001-04-02

Family

ID=19903274

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19992102A NO309798B1 (no) 1999-04-30 1999-04-30 Peptidblanding, samt farmasoytisk sammensetning og kreftvaksine som innbefatter peptidblandingen

Country Status (7)

Country Link
EP (1) EP1173199A1 (no)
JP (1) JP2002543149A (no)
AR (1) AR023806A1 (no)
AU (1) AU4438900A (no)
CA (1) CA2372187A1 (no)
NO (1) NO309798B1 (no)
WO (1) WO2000066153A1 (no)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2836684B1 (fr) * 2002-03-04 2004-12-17 Inst Nat Sante Rech Med Peptides ras mutes et leur utilisation en immunotherapie
US8343502B2 (en) 2002-12-16 2013-01-01 Globeimmune, Inc. Yeast-based vaccines as immunotherapy
AU2003301021C1 (en) * 2002-12-16 2010-02-18 Globelmmune, Inc. Yeast-based vaccines as immunotherapy
JP2009531068A (ja) 2006-03-27 2009-09-03 グローブイミューン，インコーポレイテッド Ｒａｓ変異並びにこれに関連する組成物及び方法
GB0821616D0 (en) 2008-11-26 2008-12-31 Lytix Biopharma As Compounds
DK2473605T3 (en) * 2009-09-03 2018-05-28 Pfizer Vaccines Llc PCSK9-VACCINE
EP3023788B1 (en) 2010-05-14 2020-02-12 The General Hospital Corporation Compositions of tumor specific neoantigens for use in treating tumours
CN102060929A (zh) * 2010-06-07 2011-05-18 夏书奇 T细胞免疫平衡肽
US10801070B2 (en) 2013-11-25 2020-10-13 The Broad Institute, Inc. Compositions and methods for diagnosing, evaluating and treating cancer
WO2015085147A1 (en) 2013-12-05 2015-06-11 The Broad Institute Inc. Polymorphic gene typing and somatic change detection using sequencing data
EP3357505A1 (en) 2013-12-09 2018-08-08 Targovax Asa T-cell preparations and mixtures
WO2015095811A2 (en) 2013-12-20 2015-06-25 The Board Institute Inc. Combination therapy with neoantigen vaccine
WO2015169804A1 (en) * 2014-05-06 2015-11-12 Targovax As Peptide vaccine comprising mutant ras peptide and chemotherapeutic agent
WO2016100977A1 (en) 2014-12-19 2016-06-23 The Broad Institute Inc. Methods for profiling the t-cel- receptor repertoire
EP3234193B1 (en) 2014-12-19 2020-07-15 Massachusetts Institute of Technology Molecular biomarkers for cancer immunotherapy
PE20180670A1 (es) * 2015-05-20 2018-04-19 Broad Inst Inc Neoantigenos compartidos
EP3310808A1 (en) * 2015-06-16 2018-04-25 Targovax Asa Mutated fragments of the ras protein
EP3574116A1 (en) 2017-01-24 2019-12-04 The Broad Institute, Inc. Compositions and methods for detecting a mutant variant of a polynucleotide
KR20190110612A (ko) 2017-02-01 2019-09-30 모더나티엑스, 인크. 활성화 종양유전자 돌연변이 펩티드를 인코드하는 면역조절 치료 mrna 조성물
CN110709094A (zh) * 2017-02-03 2020-01-17 威斯康星州医药大学股份有限公司 Kras肽疫苗组合物及其使用方法
WO2019126186A1 (en) 2017-12-18 2019-06-27 Neon Therapeutics, Inc. Neoantigens and uses thereof
CN114681600A (zh) * 2018-10-19 2022-07-01 杭州纽安津生物科技有限公司 通用性多肽疫苗及其在制备治疗/预防胰腺癌药物中的应用
US20220313803A1 (en) * 2019-01-07 2022-10-06 Brightpath Biotherapeutics Co., Ltd. Novel neoantigens and cancer immunotherapy using same
IL266728B (en) * 2019-05-19 2020-11-30 Yeda Res & Dev Identification of recurrent mutant neopeptides
EP4106786A1 (en) * 2020-02-19 2022-12-28 Aelin Therapeutics Molecules targeting proteins
MX2022010191A (es) * 2020-02-19 2022-11-14 Aelin Therapeutics Moleculas dirigidas a proteina ras mutante.
WO2022219152A1 (en) * 2021-04-16 2022-10-20 Oblique Therapeutics Ab Kras antibodies
WO2024112821A1 (en) * 2022-11-22 2024-05-30 Elixirgen Therapeutics, Inc. Antigens for cancer immunotherapy

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4957859A (en) * 1988-02-16 1990-09-18 Hoffmann-La Roche Inc. Antibodies for transforming ras protein
GB9103974D0 (en) * 1991-02-26 1991-04-10 Norsk Hydro As Therapeutically useful peptides or peptide fragments
WO1997040156A1 (en) * 1996-04-19 1997-10-30 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Mutated ras peptides for generation of cd8+ cytotoxic t lymphocytes
GB9620350D0 (en) * 1996-09-30 1996-11-13 Maudsley David J Cancer vaccine
GB2328689A (en) * 1997-08-27 1999-03-03 Norsk Hydro As Peptides based on the p21 ras proto-oncogene protein for the treatment of cancer

Also Published As

Publication number Publication date
NO309798B1 (no) 2001-04-02
JP2002543149A (ja) 2002-12-17
NO992102D0 (no) 1999-04-30
AU4438900A (en) 2000-11-17
WO2000066153A1 (en) 2000-11-09
EP1173199A1 (en) 2002-01-23
AR023806A1 (es) 2002-09-04
CA2372187A1 (en) 2000-11-09

Similar Documents

Publication Publication Date Title
NO992102L (no) Peptidblanding, samt farmasøytisk sammensetning og kreftvaksine som innbefatter peptidblandingen
NL1015859A1 (nl) Farmaceutische preparaten.
NO20032438D0 (no) Orto- og metasubstituerte bis-arylforbindelser, deres fremstilling og anvendelse samt farmasöytiske preparater inneholdende forbindelsene
ITTO20010005A0 (it) Formulazione farmaceutica.
NO20033556D0 (no) Farmasöytiske preparater
EE200200038A (et) Konservitud farmatseutilised preparaadid
TR199901077A3 (tr) Ispençiyari formülasyonlar.
NO20015175D0 (no) Farmasöytisk sammensetning
ATE490327T1 (de) Impfstoffzusammensetzung
NO20005146D0 (no) Tienylazolylalkoksyetanaminer, deres fremstilling og deres anvendelse som medikamenter
NO20006138D0 (no) Substituerte indolinoner, fremstilling og anvendelse derav som medikamenter
NO20022606D0 (no) Farmasöytiske kombinasjoner
NO20016247D0 (no) Streptograminderivater, deres fremstilling og preparater inneholdende derivatene
IT1311921B1 (it) Composti farmaceutici.
NO20022022D0 (no) N-guanidinoalkylamider, deres fremstilling, deres anvendelse og farmasöytiske preparater omfattende disse
NO983472D0 (no) Taxoider, deres fremstilling og farmas°ytiske preparater inneholdende taxoidene
DK1118610T3 (da) Benzensulfonamid-derivater, fremgangsmåde til fremstilling heraf samt farmaceutiske sammensætninger indeholdende derivaterne
DE69926012D1 (de) Arzneizubereitungen
FI4488U1 (fi) Farmaseuttinen koostumus
NO20014692L (no) 3-amidinobenzensulfonamidderivater, medisinske sammensetninger inneholdende slike samt intermediater vedfremstillingen derav
EE200100697A (et) Farmatseutiline kompleks
AR025867A1 (es) Formulacion portasdora farmaceutica
DE69906934D1 (de) Arzneizubereitungen
NO20020404L (no) Streptograminderivater, deres fremstilling samt preparater inneholdende derivatene
NO20015617L (no) Spiroimidazolderivater, deres fremstilling, deres anvendelse og farmasöytiske preparater som innbefatter slike derivater

Legal Events

Date Code Title Description
CREP Change of representative

Representative=s name: ZACCO NORWAY AS POSTBOKS 765 SENTRUM OSLO, 0106 NO

MM1K Lapsed by not paying the annual fees